Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy
Shirin Lak, Valérie Janelle, Anissa Djedid, Gabrielle Boudreau, Ann Brasey, Véronique Lisi, Ali Smaani, Cédric Carli, Lambert Busque, Vincent‐Philippe Lavallée, Jean‐Sébastien Delisle
Abstract
T cell manufacturing can be improved by using TIM3 and PD-L1/PD-1 axis blockade in combination. This approach is readily applicable to several adoptive immunotherapy strategies.
Topics & Concepts
Cytotoxic T cellImmunotherapyT-cell receptorT cellAntigenBlockadeCD8Adoptive cell transferBiologyCancer immunotherapyImmunologyStreptamerEx vivoCancer researchImmune systemReceptorIn vivoIn vitroBiochemistryBiotechnologyCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology